| __timestamp | Exelixis, Inc. | Iovance Biotherapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 50829000 | 9335772 |
| Thursday, January 1, 2015 | 57305000 | 12390000 |
| Friday, January 1, 2016 | 116145000 | 25602000 |
| Sunday, January 1, 2017 | 159362000 | 21262000 |
| Monday, January 1, 2018 | 206366000 | 28430000 |
| Tuesday, January 1, 2019 | 228244000 | 40849000 |
| Wednesday, January 1, 2020 | 293355000 | 60210000 |
| Friday, January 1, 2021 | 401715000 | 83664000 |
| Saturday, January 1, 2022 | 459856000 | 104097000 |
| Sunday, January 1, 2023 | 542705000 | 106916000 |
| Monday, January 1, 2024 | 492128000 |
Cracking the code
In the competitive world of biotechnology, managing Selling, General, and Administrative (SG&A) expenses is crucial for financial health. Exelixis, Inc. and Iovance Biotherapeutics, Inc. have taken different paths in this regard over the past decade. From 2014 to 2023, Exelixis saw a staggering 967% increase in SG&A expenses, reflecting its aggressive growth strategy. In contrast, Iovance's SG&A costs rose by 1,045%, albeit from a much smaller base, indicating a more cautious expansion.
By 2023, Exelixis's SG&A expenses were nearly five times higher than Iovance's, suggesting a more substantial investment in administrative and sales functions. This divergence highlights the strategic choices each company has made in scaling their operations. As investors and industry watchers analyze these trends, the question remains: which strategy will yield better long-term returns?
SG&A Efficiency Analysis: Comparing Johnson & Johnson and Exelixis, Inc.
Operational Costs Compared: SG&A Analysis of Amgen Inc. and Exelixis, Inc.
Cost Management Insights: SG&A Expenses for argenx SE and Iovance Biotherapeutics, Inc.
Exelixis, Inc. or Ultragenyx Pharmaceutical Inc.: Who Manages SG&A Costs Better?
Operational Costs Compared: SG&A Analysis of Exelixis, Inc. and Merus N.V.
Cost Management Insights: SG&A Expenses for Exelixis, Inc. and HUTCHMED (China) Limited
Comparing SG&A Expenses: Exelixis, Inc. vs Novavax, Inc. Trends and Insights
SG&A Efficiency Analysis: Comparing Exelixis, Inc. and MiMedx Group, Inc.
Cost Management Insights: SG&A Expenses for Madrigal Pharmaceuticals, Inc. and Iovance Biotherapeutics, Inc.
Who Optimizes SG&A Costs Better? Grifols, S.A. or Iovance Biotherapeutics, Inc.
Bausch Health Companies Inc. vs Iovance Biotherapeutics, Inc.: SG&A Expense Trends
SG&A Efficiency Analysis: Comparing Amicus Therapeutics, Inc. and Iovance Biotherapeutics, Inc.